
Samuel W Brady

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11467102/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nature Medicine, 2011, 17, 461-469.	30.7	466
2	Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia. Blood, 2020, 135, 41-55.	1.4	171
3	Combating subclonal evolution of resistant cancer phenotypes. Nature Communications, 2017, 8, 1231.	12.8	124
4	St. Jude Cloud: A Pediatric Cancer Genomic Data-Sharing Ecosystem. Cancer Discovery, 2021, 11, 1082-1099.	9.4	109
5	Genomes for Kids: The Scope of Pathogenic Mutations in Pediatric Cancer Revealed by Comprehensive DNA and RNA Sequencing. Cancer Discovery, 2021, 11, 3008-3027.	9.4	88
6	Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations. Nature Communications, 2020, 11, 5183.	12.8	87
7	Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Disease–Directed Therapy. Blood Cancer Discovery, 2021, 2, 326-337.	5.0	71
8	PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition. Cancer Biology and Therapy, 2015, 16, 402-411.	3.4	44
9	Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer. Cancer Research, 2015, 75, 4863-4875.	0.9	44
10	Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer. Cancer Research, 2012, 72, 4417-4428.	0.9	42
11	The Clonal Evolution of Metastatic Osteosarcoma as Shaped by Cisplatin Treatment. Molecular Cancer Research, 2019, 17, 895-906.	3.4	40
12	Therapeutic and prognostic insights from the analysis of cancer mutational signatures. Trends in Genetics, 2022, 38, 194-208.	6.7	39
13	The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma. Nature Communications, 2021, 12, 6468.	12.8	35
14	Enhanced PI3K p110α Signaling Confers Acquired Lapatinib Resistance That Can Be Effectively Reversed by a p110α-Selective PI3K Inhibitor. Molecular Cancer Therapeutics, 2014, 13, 60-70.	4.1	34
15	HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer. Molecular Oncology, 2015, 9, 586-600.	4.6	31
16	The acquisition of molecular drivers in pediatric therapy-related myeloid neoplasms. Nature Communications, 2021, 12, 985.	12.8	31
17	Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapse. Nature Cancer, 2021, 2, 819-834.	13.2	24
18	Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors. Cell Research, 2014, 24, 542-559.	12.0	23

SAMUEL W BRADY

#	Article	IF	CITATIONS
19	Exploration of Coding and Non-coding Variants in Cancer Using GenomePaint. Cancer Cell, 2021, 39, 83-95.e4.	16.8	18
20	A`one-two punch' therapy strategy to target chemoresistance in estrogen receptor positive breast cancer. Translational Oncology, 2021, 14, 100946.	3.7	8
21	The landscape of coding RNA editing events in pediatric cancer. BMC Cancer, 2021, 21, 1233.	2.6	7
22	Targeting Aberrant p70S6K Activation for Estrogen Receptor–Negative Breast Cancer Prevention. Cancer Prevention Research, 2017, 10, 641-650.	1.5	4
23	Therapy-induced mutagenesis in relapsed ALL is supported by mutational signature analysis. Blood, 2020, 136, 2235-2237.	1.4	1